NHT today announced Study on AGuIX® Nanoparticles Enhancing Cervical Cancer Treatment
Archives News 2024
NH TherAguix Announces the completion of Phase I Recruitment for the Pancreas Cohort and the entry into Phase II in the NANOSMART phase Ib/II trial.
NHT today announced the transition to the Phase II randomized part of the NANOSMART study in the cohort of patients with pancreatic tumors
Nature’s Scientific Reports publishes an article describing the quantification of novel radio-enhancer AGuIX® developed in brain metastases
NH TherAguix (NHT), announced the publication in the peer-reviewed journal Scientific Reports, part of the Nature group, of an article describing a method for quantifying its next-generation radio-enhancer, AGuIX®, after tumor targeting. The article highlights the MRI biomarker properties of AGuIX® in addition to its radio-enhancing properties when combined with radiotherapy.
NH TherAguix receives FDA Fast Track designationfor AGuIX®
NH TherAguix receives FDA Fast Track designation for AGuIX®, its novel radio-enhancer in the treatment of malignant gliomas, and provides an update on its developments and prospects.
NH TherAguix appoints Jean-Philippe Del as Chief Financial Officer.
NH TherAguix announced the appointment of Jean-Philippe Del as Chief Financial Officer (CFO).